Preliminary PET study of (18)F-FC119S in normal and Alzheimer's disease models.

To evaluate the efficacy of F-18-FC119S as a positron emission tomography (PET) radiopharmaceutical for the imaging of Alzheimer's disease (AD), we studied the drug absorption characteristics and distribution of F-18-FC119S in normal mice. In addition, we evaluated the specificity of F-18-FC119S for beta-amyloid (A beta) in the AD group of an APP/PS1 mouse model and compared it with that in the wild-type (WT) group. The behavior of F-18-FC119S in the normal mice was characteristic of rapid brain uptake and washout patterns. In most organs, including the brain, F-18-FC119S reached its maximum concentration within 1 min and was excreted via the intestine. Brain PET imaging of F-18-FC119S showed highly specific binding of the molecule to A beta in the cortex and hippocampus. The brain uptake and binding values for the AD group were higher than those for the WT group. These results indicated that F-18-FC119S would be a candidate PET imaging agent for targeting A beta plaque.